Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

<h4>Background</h4>Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the 'preclinical' stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and j...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Richard J Perrin, Rebecca Craig-Schapiro, James P Malone, Aarti R Shah, Petra Gilmore, Alan E Davis, Catherine M Roe, Elaine R Peskind, Ge Li, Douglas R Galasko, Christopher M Clark, Joseph F Quinn, Jeffrey A Kaye, John C Morris, David M Holtzman, R Reid Townsend, Anne M Fagan
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2011
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/14913627f3684daeb666751f635a0bc9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/14913627f3684daeb666751f635a0bc9

Documents similaires